Besides RU-486, a GR antagonist, is used for treatment of several cancers, such as breast, ovarian, prostate, and glaucoma, and has been shown to sensitize renal carcinoma cells to TRAIL-induced apoptosis through up-regulation of DR5 and down-regulation of c-FLIP(L) and Bcl-2 [66]. This evidence concerns the gene BCL2 and glaucoma.